首页> 外文期刊>Human vaccines & immunotherapeutics. >Characteristics and viral propagation properties of a new human diploid cell line, walvax-2, and its suitability as a candidate cell substrate for vaccine production
【24h】

Characteristics and viral propagation properties of a new human diploid cell line, walvax-2, and its suitability as a candidate cell substrate for vaccine production

机译:新型人类二倍体细胞系walvax-2的特性和病毒繁殖特性及其作为疫苗生产候选细胞底物的适用性

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Human diploid cell strains (HDCSs), possessing identical chromosome sets known to be free of all known adventitious agents, are of great use in developing human vaccines. However it is extremely difficult to obtain qualified HDCSs that can satisfy the requirements for the mass production of vaccines. We have developed a new HDCS, Walvax-2, which we derived from the lung tissue of a 3-month-old fetus. We established primary, master and working cell banks successfully from reconstituted frozen cells. Observations during the concurrent propagation of Walvax-2 and MRC-5 cells revealed differences in terms of growth rate, cell viability and viral sensitivities. Specifically, Walvax-2 cells replicated more rapidly than MRC-5 cells, with Walvax-2 cells attaining the same degree of confluence in 48hours as was reached by MRC-5 cells in 72hours. Moreover, Walvax-2 cells attained 58 passages of cell doublings whereas MRC-5 reached 48 passages during this period. We also assessed the susceptibility of these cells to rabies, hepatitis A, and Varicella viruses. Analysis of virus titers showed the Walvax-2 cells to be equal or superior to MRC-5 cells for cultivating these viruses. Furthermore, in order to characterize the Walvax-2 cell banks, a series of tests including cell identification, chromosomal characterization, tumorigenicity, as well as tests for the presence of microbial agents, exogenous viruses, and retroviruses, were conducted according to standard international protocols. In conclusion, results from this study show that Walvax-2 cell banks are a promising cell substrate and could potentially be used for the manufacturing of HDCVs.
机译:具有已知不含所有已知外来因子的相同染色体组的人类二倍体细胞株(HDCS)在开发人类疫苗中具有很大的用途。但是,获得满足大规模生产疫苗要求的合格HDCS非常困难。我们已经开发了一种新的HDCS Walvax-2,它是从一个3个月大的胎儿的肺组织中获得的。我们成功地从重建的冷冻细胞中建立了原代,主代和工作细胞库。 Walvax-2和MRC-5细胞同时繁殖期间的观察表明,在生长速率,细胞活力和病毒敏感性方面存在差异。具体来说,Walvax-2细胞的复制速度比MRC-5细胞要快,Walvax-2细胞在48小时内达到的融合程度与MRC-5细胞在72小时内达到的融合程度相同。此外,在此期间,Walvax-2细胞获得了58倍的细胞传代,而MRC-5细胞达到了48倍。我们还评估了这些细胞对狂犬病,甲型肝炎和水痘病毒的敏感性。病毒滴度分析表明,用于培养这些病毒的Walvax-2细胞与MRC-5细胞相同或更高。此外,为了表征Walvax-2细胞库,根据标准国际协议进行了一系列测试,包括细胞鉴定,染色体表征,致瘤性以及微生物制剂,外源病毒和逆转录病毒的存在测试。总之,这项研究的结果表明,Walvax-2细胞库是一种很有前途的细胞底物,可潜在地用于HDCV的生产。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号